On 11 June, co-authored with David Mun of JMUN ADVISORS, I published the theoretical argument: that de-prioritising Europe under MFN doesn't resolve the pricing exposure — it removes the revenue while leaving the risk intact. Eight days later, Ramagopalan and Ryan published the empirical evidence in the Journal of Comparative Effectiveness Research. The data confirms the mechanism is already operating. What follows is the commercial read on what it means.

The divergence is the signature

Ramagopalan and Ryan compared new-product launches across matched 12-month windows before and after the MFN executive order (May 2025). The pattern is unambiguous.

Launch decline by cohort — post MFN executive order (May 2025)
11 EU member states subject to JCA −37.8%
19-country GLOBE/GUARD reference basket −29.9%
United States −10.5%
Non-orphan products — EU (11 member states) −46.1%
Non-orphan products — United States 0.0%

That divergence — flat US, steep EU decline for the same products — cannot be explained by a general post-2025 industry slowdown, which would have depressed both markets equally. It is the signature of reference-pricing spillover: manufacturers maintaining US launches while pulling back from the markets whose prices enter the MFN comparator basket. The mechanism is now empirically documented.

Orphan products have a buffer. It has an expiry date.

The most actionable finding is the interaction between orphan status and JCA scope.

Across the EU reference markets, orphan-designated products showed considerably more launch resilience than non-orphan products. That resilience is real — but its explanation is structural, not protective. For rare disease assets, rest-of-world revenues typically dominate what analysts call net present value — NPV. This is the total worth of an asset's future revenues expressed in today's money: what a drug is worth right now, accounting for all the revenue it is expected to generate over its commercial lifetime. For rare disease products, European revenues often represent a larger share of that total than for mainstream indications, where US revenues dominate. The marginal damage to achievable US pricing from a European launch is therefore small relative to the damage to overall asset value from foregoing that launch. Orphan products have less to gain from delay and more to lose.

"The only subgroup that escaped material decline was the one exposed to neither strong MFN pressure nor JCA preparation burden. That is not a policy protection. It is a temporary structural position."

The JCA interaction sharpens this considerably. JCA currently applies mandatorily to oncology and advanced therapy medicinal products (ATMPs) — orphan products are not in scope as a general category until 2028. But orphan oncology and orphan ATMP products are in scope now, and the data shows it.

Orphan launch change — 11 EU JCA member states, by JCA scope
Orphan products outside JCA scope −1.4%
Orphan oncology + ATMP products inside JCA scope −22.9%

A 22 percentage-point differential. The only subgroup that escaped material decline was the one exposed to neither strong MFN reference-pricing pressure nor JCA preparation burden. That is not a policy protection. It is a temporary structural position.

2028 closes the window

JCA expands to all orphan medicinal products in 2028. The launch resilience currently observed in orphan products outside JCA scope will not persist once that exemption is removed — particularly as the mandatory MFN models reach operational maturity over the same period.

The closing window
Orphan assets currently outside JCA scope are sitting in a buffer that disappears in 2028

Companies with orphan assets in non-oncology, non-ATMP therapeutic areas currently show essentially flat EU launch rates. The paper's findings show exactly what happens when JCA scope expands: a 22 percentage-point swing, already visible in orphan oncology and ATMP products today. The decisions being made now — on EU launch sequencing, licensing deal structures, and JCA evidence investment — will determine whether companies are positioned ahead of that shift or reacting to it.

What the numbers require

Three questions companies with orphan or rare disease assets should be asking now, not in 2028.

01 What is the NPV calculus for your specific asset? For products where rest-of-world revenues dominate total asset value, EU launch delay destroys more value than it protects. For non-orphan products where US revenues dominate, delay is commercially defensible. Know which category you're in before making the launch sequencing decision.
02 Are you in a GLOBE or GUARD therapeutic class? GLOBE covers provider-administered drugs across seven classes including antineoplastics and immunological agents. GUARD covers self-administered drugs across 17 classes. The MFN pressure is not uniform — it tracks the therapeutic category. Orphan status offers partial protection now; for oncology and ATMP assets, that protection has already eroded.
03 If Europe is being partnered out, what do the deal terms look like under MFN conditions? The EU list price negotiated by a licensing partner enters the MFN comparator basket regardless of who controls it. Terms signed today will operate in a world where the mechanism is fully operational. The paper quantifies what that means for launch volumes. The deal structuring question is whether your terms account for it.

The theoretical argument was published on 11 June. The empirical evidence arrived on 19 June. The compounding of MFN and JCA on European launches is now documented in the peer-reviewed literature.

The window for early positioning is narrowing. The data says so.